Navigation Links
BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
Date:12/3/2007

idated markers of renal function and injury will help define a straightforward clinical and regulatory path, and this program also leverages our biologics manufacturing and process development infrastructure and expertise."

IgA nephropathy or Berger's disease is a primary glomerulonephritis characterized by mesangial deposits of IgA complexes. Over time, these deposits damage the kidney, causing 20% of adults with the disorder to progress to end stage renal disease (ESRD). Patients in ESRD require dialysis or a kidney transplant to survive. In the United States, approximately 800 patients per year develop ESRD caused by IgA nephropathy out of the 40,000 patients affected by the disorder.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release. About IGAN Biosciences

IGAN Biosciences develops novel, safe biotherapeutics for diseases in which current treatments are ineffective. The company's lead compound, a protease designed f
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
7. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... With the ability to record continuously at ... than 15 minutes, Fastec Imaging has brought the same ease-of-use ... imaging. “Finally, a high speed camera that can be used ... everyday lives.” proclaims Matt Kearney, VP of Sales for Fastec ... demystify and simplify the traditionally complicated workflow of a high ...
(Date:7/23/2014)... Astra Nova Training , a ... pharma training services, and the Alliance for ... non-profit integrating the expertise and investments of research ... system for clinical trials, are pleased to announce ... of industry professionals through improved and easily available ...
(Date:7/22/2014)... Researchers from the National Institute of Standards and ... have demonstrated a new design for an atomic ... comb, or a microcomb. , The microcomb clock, ... of the new journal Optica ,* is ... microcomb, and its accurate conversion of optical frequencies ...
(Date:7/22/2014)... Nuclear reactors are used to produce ... fission chain reaction in nuclear reactors is used to ... drive a power- generating turbine. Currently nuclear reactors are ... electricity production. Nuclear reactor market is expected to grow ... proposed nuclear reactor projects. , Early buyers will receive ...
Breaking Biology Technology:Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3'Comb on a chip' powers new NIST/Caltech atomic clock design 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Calif., March 20, 2012 Cepheid (NASDAQ: ... of Medicine and Dentistry of New Jersey (UMDNJ), it ... Health to develop sample processing and amplification methods for ... reaction (PCR) on the GeneXpert® System. The $1.3 million ...
... March 20, 2012 Heptares Therapeutics, the ... company of Shire PLC (LSE: SHP, NASDAQ: ... its exclusive option to license a novel adenosine A ... in preclinical development. Adenosine A 2A is a ...
... 19, 2012  MiMedx Group, Inc. (OTCBB: MDXG), an ... regenerative biomaterials and bioimplants processed from human amniotic ... distribution agreement with Systagenix, whereby Systagenix will co-market ... specifically processed from amniotic tissue, EpiFix® offers a ...
Cached Biology Technology:Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 2Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 4Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 2MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 3
(Date:7/23/2014)... strength, but it also holds the promise of a ... to convert sunlight into a clean, efficient alternative fuel. ... group using spinach to study the proteins involved in ... energy into carbohydrates used to power cellular processes. , ... efficient system ever built, capable of converting the energy ...
(Date:7/23/2014)... Migratory songbirds are disappearing, and though conservationists are examining ... habitat, acid rain and light pollution, a key piece ... birds go once they leave their breeding sites, and ... , To answer this question, a team of researchers ... migratory connectivity map produced for a songbird, using tracking ...
(Date:7/23/2014)... planet,s soil releases about 60 billion tons of carbon ... than that released by burning fossil fuels. This happens ... of carbon is balanced by carbon coming into the ... as well as by the underground activities of plant ... rising temperatures increase the rate of soil respiration. As ...
Breaking Biology News(10 mins):Spinach could lead to alternative energy more powerful than Popeye 2York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2Climate change and the soil 2
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... has on pregnancy, are urging men to get ... development. Reproductive experts from the University of ... father,s obesity negatively impacts sperm, resulting in smaller ... While the health risks surrounding obesity ...
... Venture has developed a framework to evaluate the risk ... A paper based on this work: A framework for ... has been published in the Malaria Journal ... anti-infective drug, so it is important when developing new ...
Cached Biology News:As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2Thinking about kids? Man, you gotta shed the kilos 2MMV develops framework to assess risk of resistance for antimalarial compounds 2
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
Biology Products: